卵巢癌诊疗风险调整模型对短期生存的分析
基于加州癌症登记处1996–2017年I–IV期浸润性上皮性卵巢癌的回顾性人群研究,用观察值与期望值比(O/E)衡量医院对指南的依从性并分层。35,725例、443家医院中,高O/E医院初始治疗是短期生存改善的独立预测因素,生存优势集中在诊断后短期。
要点
- 高O/E医院初始治疗与3、6、12、24个月生存改善独立相关。
- 高O/E医院总体中位生存72.5个月,低O/E医院47.0个月。
- 白种人、西班牙裔、亚裔/太平洋岛民及不同社会经济阶层均见关联。
核心结论
- 在高O/E医院接受卵巢癌诊疗是结局改善的独立预测因素。
- 该生存优势在诊断后短期时间范围内权重更大。
研究设计与样本
- 回顾性人群研究,纳入1996–2017年加州癌症登记处报告的I–IV期浸润性上皮性卵巢癌。
- 研究人群35,725例,分布于443家医院。
- 用拟合logistic回归模型按患者和疾病特征进行风险调整,计算各医院O/E并按医院年病例量分层。
- 用Cox比例风险模型分析3、6、12、24个月生存,并按社会人口学特征分层。
主要发现
- 低O/E医院占26.4%病例,中等O/E医院占55.5%,高O/E医院占18.1%。
- 高O/E医院总体中位生存72.5个月(95% CI = 68.6–78.6个月),中等O/E医院68.6个月(95% CI = 65.9–71.6个月),低O/E医院47.0个月(95% CI = 44.2–49.2个月)。
- 以高O/E医院为参照(HR = 1.00),低O/E医院3个月HR = 1.46(95% CI = 1.29–1.65),6个月HR = 1.35(95% CI = 1.22–1.50),12个月HR = 1.27(95% CI = 1.17–1.38),24个月HR = 1.19(95% CI = 1.11–1.27)。
- 白种人、西班牙裔、亚裔/太平洋岛民(A/PI)、各社会经济阶层及所有支付类别中,高O/E诊疗与短期生存改善均见显著独立关联。
关键数值与推荐
- 高O/E医院总体中位生存72.5个月(95% CI = 68.6–78.6个月),中等O/E医院68.6个月(95% CI = 65.9–71.6个月),低O/E医院47.0个月(95% CI = 44.2–49.2个月)。
- 与高O/E医院(HR = 1.00)相比,低O/E医院3个月HR = 1.46(95% CI = 1.29–1.65),6个月HR = 1.35(95% CI = 1.22–1.50),12个月HR = 1.27(95% CI = 1.17–1.38),24个月HR = 1.19(95% CI = 1.11–1.27)。
临床怎么用
- 原文未据此给出推荐,结论为高O/E医院诊疗是结局改善的独立预测因素,生存优势集中于诊断后短期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify the impact on short-term ovarian cancer survival associated with treatment at high-performing hospitals using the observed-to-expected ratio (O/E) for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care. METHODS: This was a retrospective population-based study of stage I-IV invasive epithelial ovarian cancer reported to California Cancer Registry 1996-2017. A fit logistic regression model, risk-adjusted for patient and disease characteristics, was used to calculate O/E for each hospital stratified by hospital annual case volume. Cox proportional hazards model was used for survival analyses at 3, 6, 12, 24 months and stratified according to sociodemographic characteristics. RESULTS: The study population included 35,725 subjects treated at 443 hospitals: Low-O/E - 26.4% of cases; Intermediate-O/E - 55.5% of cases; and High-O/E - 18.1% of cases. Overall median survival by hospital category was: High-O/E = 72.5 months (95% CI = 68.6-78.6 months), Intermediate-O/E = 68.6 months (95% CI = 65.9-71.6 months), Low-O/E = 47.0 months (95% CI = 44.2-49.2 months). Initial treatment at a High-O/E hospital (HR = 1.00) was a statistically significant and independent predictor of improved short-term survival compared to Low-O/E hospitals at 3 months (HR = 1.46, 95% CI = 1.29-1.65), 6 months (HR = 1.35, 95% CI = 1.22-1.50), 12 months (HR = 1.27, 95% CI = 1.17-1.38), and 24 months (HR = 1.19, 95% CI = 1.11-1.27). Significant and independent associations between improved sort-term survival and High/O/E care were observed for Whites, Hispanics, Asian/Pacific Islanders (A/PI), across SES strata, and among all payer categories. CONCLUSION: Ovarian cancer care at a High-O/E hospital is an independent predictor of improved outcome and the survival advantage is disproportionately weighted toward the short-term time horizon following diagnosis.
引用
- Hari A, Chang J, Villanueva C, et al. Short-term survival analysis of a risk-adjusted model for ovarian cancer care. Gynecol Oncol. 2024. PMID: 38309029. doi:10.1016/j.ygyno.2024.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。